Scilex Holding Company Derivative Liability
Scilex Holding Company (SCLX) had Derivative Liability of $32.19 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities
us-gaap:DerivativeLiabilities · last filed 2026-08-14
- 2026-06-30: Derivative Liability $32.19M.
- 2026-03-31: Derivative Liability $25.54M.
- 2025-12-31: Derivative Liability $50.60M.
- 2025-09-30: Derivative Liability $81.98M.
| Period end | Derivative Liability | Derivative Liability as first filed |
|---|---|---|
| 2026-06-30 | $32.19M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $25.54M 10-Q · filed 2026-05-20 | |
| 2025-12-31 | $50.60M 10-Q · filed 2026-08-14 | |
| 2025-09-30 | $81.98M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $20.27M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $7.89M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | $18.30M 10-K · filed 2026-04-10 | |
| 2024-09-30 | $11.45M 10-Q · filed 2025-01-17 | |
| 2024-06-30 | $30.00M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $6.94M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $1.52M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $2.10M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $6.57M 10-Q · filed 2023-08-11 | |
| 2023-03-31 | $6.48M 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $1.23M 10-K · filed 2024-03-12 | |
| 2022-09-30 | $1.16M 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $1.23M 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $3.76M 10-Q · filed 2022-05-16 | |
| 2021-12-31 | $35.70M 10-K · filed 2023-03-07 | $3.35M 10-K · filed 2022-02-24 |
| 2021-09-30 | $4.86M 10-Q/A · filed 2021-12-08 | |
| 2021-06-30 | $3.69M 10-Q/A · filed 2021-08-24 | |
| 2021-03-31 | $3.63M 10-Q · filed 2021-07-23 | |
| 2020-12-31 | $35.40M 10-K · filed 2023-03-07 | |
| 2019-12-31 | $33.40M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |